Compare BHP Billiton Limited (BHP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Incyte Corporation — how do they compare? BHP Billiton Limited trades at $90.34 (market cap $229.15B), while Incyte Corporation trades at $120.59 (market cap $24.54B). The key difference: BHP Billiton Limited is far larger — about 9.3× Incyte Corporation's market cap, and BHP Billiton Limited pays a 2.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BHP | INCY | |
|---|---|---|
Market Cap | $229.15B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $129.93 |
52-Week Low | $52.14 | $81.61 |
Enterprise Value | $243.35B | $20.04B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.36, down 0.28% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q4 2025 earnings, missing EPS estimates, while Q2 2025 beat expectations. Revenue for 2024 was $55.66B with a net income margin of 18.97%, though profitability has fluctuated in recent years. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production and revenue streams.
Outlook is cautious due to operational risks from strikes and volatile commodity prices, but strong cash flow and institutional buying support long-term value. Analysts are predominantly neutral with 65% hold ratings, reflecting balanced risk-reward. Key risks include labor disputes and copper output misses, while opportunities lie in AI-driven copper demand growth and cost management.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
